CUSMA must do more than protect trade—it must secure Canada’s life sciences future

The U.S. may begin to apply tariffs or other barriers to enhance its domestic production, and if that happens, Canada will need a plan not just to respond, but also to thrive.
Our domestic ability to invent, manufacture, and export medical technologies, devices, diagnostics, drugs, and vaccines is not just an economic opportunity, but it is also a matter of survival, writes Cameron L. Groome.

As Canada enters further negotiations to renew the Canada–United States–Mexico Agreement, much of the focus will understandably be on familiar sectors such as automobiles, aluminum, steel, and forest products. But another sector, equally vital to Canada’s national and ...

To keep reading, subscribe and become a political insider.

Only $7.76 a week for an annual subscription.

Enjoy unlimited website access and the digital newspaper.

Cancel anytime.


Already a Subscriber?

Get Innovation & Industry Newsletter

From investment to regulation, the policies, decisions and people working on industry and innovation. Tuesday.


By entering your email address you consent to receive email from The Hill Times containing news, analysis, updates and offers. You may unsubscribe at any time. See our privacy policy

MORE Opinion

RELATED STORIES